



**COLORADO**

Department of Health Care  
Policy & Financing

**AGENDA: DUR BOARD MEETING**  
**Colorado Medicaid DUR**  
**Department of Health Care Policy and Financing**

Skaggs School of Pharmacy and Pharmaceutical Sciences Building  
12850 East Montview Blvd, Aurora CO 80045  
Seminar Room- Room 1000; First floor  
Parking available in the Henderson/Visitor Parking Garage

November 15, 2016  
6:00 p.m. – 9:00 p.m. Open Session

**DUR BOARD MEMBERS and CO DUR MEMBERS**

LeWayne Garrison, PharmD  
Karen Weber, DO  
Sheila Botts, PharmD  
Kerstin Froyd, MD  
James Regan, MD  
Pam Reiter, PharmD  
Alex Reish, DO  
Caroline Kicklighter, PharmD

Robert Lodge, PharmD  
Robert L Page, PharmD, MSPH  
(CO DUR)  
Nila Mahyari, PharmD (CO DUR)  
Jon Campbell, PhD (CO DUR)  
Gina Moore, PharmD

**1. Roll Call**

**2. Approval of the minutes from the August 16, 2016 meeting**

**3. Rules**

- Agenda items must be approved in advance, including requests to present information. Please contact Robert Lodge at (303) 866-3105 if you want to add an agenda item. Visitors are welcome during the open portion of the meeting only.
- Anyone wishing to provide testimony must contact the DUR Coordinator Robert Lodge (Robert.Lodge@state.co.us) at 303-866-3105 or at least 24 hours before the meeting.



## 4. Open Session

### A. Unfinished Business and General Orders

- PBMS System Implementation Update
- DUR Newsletter/Website Update
- ProDUR Criteria
- Excluded Drug Coverage Policy Update
  - Recent guidance from CMS
- Review Retro-DUR reports / Evaluation plan with Columbia University Mailman School of Public Health
- Provider Education Reports
- Quarterly Drug Utilization Reports
- Module outlook summary
- FDA updates / New Drugs

#### Update on the following:

- Hepatitis C agents
- Oral anticoagulants
- Bisphosphonates
- Erythropoiesis stimulating agents
- Hypoglycemic combinations
- Meglitinides
- DPP4 inhibitors
- GLP-1 analogues
- Thiazolidinediones
- Overactive bladder agents
- Stimulants and other ADHD agents

### B. New Business

#### Proposed Criteria for current PDL:

- Anti-emetics
- New generation antidepressants
- Anti-herpetic agents
- Oral anti-platelet
- Epinephrine products
- Oral fluoroquinolones
- Pancreatic enzymes
- Proton pump inhibitors
- Pulmonary arterial hypertension agents



- Targeted immune modulators
- Triptans

**Proposed Criteria for Other Agents:**

- Valcyte
- Rasuvo
- Yosprala

## **5. Adjourn**

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303- 866-3105 or [robert.lodge@state.co.us](mailto:robert.lodge@state.co.us) or the 504/ADA Coordinator [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

